'Highest ever' cancellation rate impairs Parexel's Q1 FY16 results
Parexel has lowered its revenue guidance for the year following cancellations worth $305m in its first quarter FY2016.
Archives for November 2, 2015
Europe plans IP waiver for pharma manufacturing
The European Commission plans to introduce a waiver to supplementary protection certificates (SPCs) to stimulate pharma manufacturing in Europe.
Placebo response may be making pain trials tougher
It has been getting harder and harder for trial sponsors to show that drugs intended to treat neuropathic pain are effective - and the reason is surprising.
Sanofi says injectable recall could cost company $110m
Sanofi’s mass recall of faulty auto-injectors will cost the French company about €100m ($110m), its CFO says.